The Food and Drug Administration as approved the first generic of a drug used to treat severe hypoglycemia. The agency has approved a generic glucagon for injection, 1 mg, from Amphastar ...

RANCHO CUCAMONGA, Calif., Dec. 29, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc., (NASDAQ: AMPH) announced that the U.S. Food and Drug Administration (“FDA”) has approved its ...

Thirty minutes after the glucagon injection the arteriovenous difference had risen to 16.9 mg. per 100 ml., ... To ascertain the effects of long-term administration of glucagon on food intake, ...

Usability research evaluating the GVOKE PFS and GVOKE HypoPen demonstrated nearly 100% success rates in administering a full dose of glucagon using the simple 2-step administration process.

The US Food and Drug Administration has approved the first-ever generic glucagon injection kit for the treatment of severe hypoglycemia in patients with diabetes and as a diagnostic aid.. The FDA ...

Glucagon injections are made with a synthetic form of glucagon and are used in an emergency. ... and is approved by the Food and Drug Administration (FDA) for adults and children 2 and over.

The intramuscular or subcutaneous injection of 1 or 2 mg. of glucagon* is easier and more convenient than the intravenous administration of glucose in the unconscious or uncooperative patient ...

SILVER SPRING, Md., July 24, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration today approved Baqsimi nasal powder, the first glucagon th ...

Today, the U.S. Food and Drug Administration approved the first generic of glucagon for injection USP, 1 mg/vial packaged in an emergency kit, for the treatment of severe hypoglycemia (very low ...

Gvoke® PFS and Gvoke HypoPen® (glucagon injection), the first prescription, ready-to-use, pre-mixed, pre-measured glucagon injection, were approved by the FDA in September 2019 for use in the ...

Glucagon is a hormone that signals the liver to release glucose into the bloodstream. It's typically given by injection to counteract severe hypoglycemia in people who have diabetes.

Austin, TX's Xeris Pharmaceuticals wrapped up a $41 million Series C financing round, as it heads toward approval (or rejection) of its diabetes injection pen for the administration of glucagon, a ...